Iris Acquisition II
IRAB.U · NYSE
About IRAB.U
- Employees
- 0
- Headquarters
- Dubai, Dubai
- Listed
- Feb 3, 2026
- Sector
- N/A
- Industry
- N/A
IRAB.U key statistics
- Market cap
- 229.28M
- Price-earnings ratio
- 0.00
- Dividend yield
- —
- Average volume
- 16
- Volume
- 3.18K
- Open price
- $10.59
- High today
- $10.45
- Low today
- $10.16
- 52 Week high
- $11.04
- 52 Week low
- $9.94
Iris Acquisition II (IRAB.U) at a glance
Iris Acquisition II (IRAB.U) last traded at $10.24, with a market cap of 229.28M and a price-to-earnings ratio of 0.00.
Today the stock has traded between $10.16 and $10.45. The current price is 0.8% above the day's low and 2.0% below its high.
Volume so far is 3.18K shares, above the average of 16 shares a day.
Over the past year Iris Acquisition II has ranged from $9.94 to $11.04, and now sits 27% of the way up that range.
Most active stocks
Highest trading volume today
- BURUNuburu$0.287−22.79%
- INTCIntel$65.76−28.58%
- SLGBSmart Logistics Global$0.3051+48.97%
- AXXAExxe Group$0.0006+50.00%
- RDARRaadr$0.0002+0.00%
- SOXLDirexion Shares ETF Trust$77.05−24.75%
- HUBCHub Cyber Security$0.1134−16.00%
- RWAXTAP Real Estate Technologies$0.0002+0.00%
- NVDANVIDIA$204.64−4.20%
- NVDGraniteShares ETF Trust$4.43+8.19%
- SPCXSpace Exploration Technologies$134.69−6.39%
- GTVHGolden Triangle Ventures$0.0001+0.00%
Newly listed
Companies that went public in the past six weeks
- GBCGEORGIA BANKING$38.38+0.27%
- BHAIUBHAV Acquisition Corp II$9.98+0.00%
- SCQCUSPACCircle Acquisition$9.99+0.05%
- LYCALycia Therapeutics$26.40−4.80%
- DAVIDAVION HEALTHCARE$1.68−37.55%
- TCXBTCGX Acquisition Corp. II$10.14−0.66%
- CTYCITY THERAPEUTICS$20.71−6.46%
- IAMIambic Therapeutics$13.43−5.95%
- AMROAmaero$5.56−3.81%
- FLSCFrazier Life Sciences Acquisition Corp. II$10.17−0.39%
- TRXBTRex Bio$13.74+1.63%
- RTSNRetension Pharmaceuticals$11.36−3.97%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.